TEST:

RAS-RAF-SEQ Assay

RAS-RAF-SEQ is a clinical grade, CLIA-validated liquid biopsy assay for the identification of gene mutations in KRAS, NRAS, BRAF, as well as PIK3CA and AKT1 for cancers impacted by the RAS-RAF and PI3K signaling pathways. Applying ultrasensitive Plasma-Safe-SeqS technology to identify mutant molecules at low levels, RAS-RAF-SEQ identifies established and emerging predictive markers, resistance mutations, frequently occurring genetic alterations associated with various cancers, and mutations that may evolve during therapy. RAS-RAF-SEQ improves clinical trial efficiency by informing therapy selection, monitoring treatment response along with disease and clonal dynamics, as we strive to optimize cancer therapy development.